2.This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.
4.Treatment Options for Locally Advanced cSCC
5.Clinical Features and Diagnosis
6.Precancerous Actinic Keratoses
7.Squamous Cell Carcinomas
9.Role of Practitioners in Disease Identification
11.Risk Factors to Watch
12.Considerations for Therapy
13.Current Treatment Options
14.Which Patients Are Candidates for Immunotherapy?
15.How Do Risks Factors Affect Pathophysiology?
16.Overview of Immune Checkpoint Response
17.Immune Checkpoint Pathway
18.Immune Checkpoint Blockade
19.Rationale for Checkpoint Inhibitor Studies
20.Phase 1: Cemiplimab (REGN2810)Study Design
21.Phase 1: Cemiplimab (REGN2810)Patient Population and Response